Alipay’s Xiang Hu Bao Online Mutual Aid Platform Attracts 100 Million Participants in One Year
27.11.2019 09:30:00 EET | Business Wire | Press release
Xiang Hu Bao, an online mutual aid platform introduced by Alipay, has attracted over 100 million participants since it was launched just over a year ago, helping health protection in China become more inclusive by making it more accessible especially for the lower income and those living in rural areas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005952/en/
100 million participants signed up for Xiang Hu Bao in one year. (Graphic: Business Wire)
As of November 22, 2019, more than 10,000 people have received financial aid for their medical needs through Xiang Hu Bao, contributed by other participants in the platform. More than two thirds of Xiang Hu Bao participants earn below RMB 100,000 (US$ 14,000) per year, while a third of them come from rural China.
Xiang Hu Bao, which literally means “mutual protection”, was launched in October 2018 and provides its participants with a basic health plan against 100 types of critical illness, including thyroid cancer, breast cancer, lung cancer, critical brain injury and acute myocardial infarction. All participants share the risk of becoming critically ill and bear the related medical expenses as a collective. While Xiang Hu Bao is not a health insurance product, it complements premium health insurance offerings in the market that have wider range and depth of coverage.
“Xiang Hu Bao was designed with inclusiveness in mind,” said Ming Yin, Vice President of Ant Financial. “We hope Xiang Hu Bao can support participants to help one another by providing a trustworthy platform in addition to the medical care protection provided by China’s social security and premium health insurance companies.”
Unlike traditional online mutual aid platforms in China, Xiang Hu Bao is more inclusive because it requires no upfront payment or admission fees. It is available to participants between 30 days and 59 years of age who meet basic health and risk criteria. When a participant makes a claim, supporting evidence must be submitted via the Alipay app and then it goes through a review and approval process. Traditionally, online mutual aid platforms in China lacked cost-effective capabilities to reduce the risk of fraud, impacting their reputation and therefore prevented them from scaling up to help those people truly in need.
On the Xiang Hu Bao platform, the entire evidence submission process is powered by Alipay’s proprietary consortium blockchain technology, which ensures the process is tamper-proof. Once claims are approved, the participant will receive a one-time payout of up to RMB 300,000 (~US$43,000), the cost of which is shared equally by the other participants. Disputed claims are escalated to an online review board that consists of qualified volunteer participants.
According to Xiang Hu Bao, around six out of ten of its participants come from third and lower tier cities, counties and rural areas. A recent survey conducted by Health Economics and Medical Security Research Center, Nankai University1 examined the annual income of Xiang Hu Bao participants and discovered that two thirds of them earn less than RMB 100,000 (~US$ 14,000). Not surprisingly, around 86% of participants cannot afford medical expenses exceeding RMB 300,000 (~US$ 43,000). Also, the survey shows that 10 percent of Xiang Hu Bao’s participants had no other health plans other than Xiang Hu Bao.
“The majority of Xiang Hu Bao’s participants are from middle or low-income communities who are at great risk of falling into poverty if they become critically ill,” said Zhu Minglai, director at the Health Economics and Medical Security Research Center, Nankai University, adding that Xiang Hu Bao has enabled low-income communities to receive basic health protection at an affordable cost and supplements other health plans provided by the public and private sectors in China.
In addition to creating value for its participants, Xiang Hu Bao also helps cultivate a greater understanding of the benefits for obtaining protection against illnesses. According to an FT Confidential Research survey,2 one in three of Xiang Hu Bao’s participants intend to buy a critical illness insurance product over the next six months, while for those who do not participate in the platform, the intention of purchasing is only 22 percent. Furthermore, sales of health policies offered by partner insurance companies on the Ant Insurance Platform have increased by over 60% as of June 2019, in comparison to October 2018 when Xiang Hu Bao was launched.
About Alipay
Operated by Ant Financial Services Group, Alipay is the world’s leading payment and lifestyle platform. Launched in 2004, Alipay serves over 1.2 billion users with its local e-wallets partners as of June 2019. Over the years, Alipay has evolved from a digital wallet to a lifestyle enabler. Users can hail a taxi, book a hotel, buy movie tickets, pay utility bills, make appointments with doctors, or purchase wealth management products directly from within the app. In addition to online payments, Alipay is expanding to in-store offline payments both inside and outside of China. Alipay’s in-store payment service covers over 50 markets across the world, and tax reimbursement via Alipay is supported in 35 markets. Alipay currently supports 27 currencies, and works with over 250 overseas financial institutions and payment solution providers to enable cross-border payments for Chinese travelling overseas and overseas customers who purchase products from Chinese e-commerce sites.
1 Source: https://mp.weixin.qq.com/s/HjRYY9jsbpe2LWhabI0ijw (in Chinese)
2 Source: https://www.ft.com/content/3bbf683e-a325-11e9-974c-ad1c6ab5efd1
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005952/en/
Contact information
Alipay / Xiang Hu Bao
Le SHEN
E: shenle.sl@antfin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
